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INTRODUCTION
Since the first cases of acquired immunodeficiency syn-
drome (AIDS) were recognized in 1981 (1, 2), it has devel-
oped into a global pandemic. The World Health Organiza-
tion estimated that approximately 42 million people world-
wide have been infected with the human immunodeficiency
virus type 1 (HIV-1), and 16,000 new infections occur each
day (3). In association with HIV-1 infection, a wide variety
of neurologic complications are now recognized, which result-
ed from opportunistic infections and neoplasm as well as direct
effects of virus itself acting alone or with as yet unknown
cofactors. These complications occur at all stages of infection
and involve any level of central and peripheral nervous sys-
tem (4-6). Approximately at least 10% of patients present
with a neurologic complaint (5-7), 30 to 50% develop neu-
rologic complications during the course of the disease (4-6),
and up to 90% show pathologic evidence of neurologic dis-
ease at autopsy (8-12).
In Korea, the number of HIV-1 seropositive populations is
increasing every year. As of June 1999, the cumulative num-
ber of documented HIV-infected patients in Korea was 964,
with 208 deaths (13). However, little has been known about
the neurologic complications of HIV-1 infection in our pop-
ulation. We report here our experience of neurologic com-
plications in the HIV-1 seropositive Korean patients and
describe the characteristic clinical features and relative fre-
quencies of the various neurologic complications.
MATERALS AND METHODS
A total of 34 patients with HIV-1 infection who admitted
to the Seoul National University Hospital between March
1998 and June 1999 were included. HIV-1 infection was
ascertained by a combination of ELISA and Western blot.
All patients were interviewed and examined by one neurol-
ogist. A full neurologic examination and peripheral nerve
conduction study (NCS) were performed in all patients. Other
diagnostic studies including detailed neuropsychologic test,
neuroimaging, cerebrospinal fluid (CSF) study, electromyo-
graphy (EMG), and neuropathologic study were performed
in selected patients. For clinical staging of these patients, we
used the “1993 revised classification system for HIV infection
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Neurologic Complications of Human Immunodeficiency 
Virus-type 1 Infection 
A wide variety of neurologic complications associated with human immunodefi-
ciency virus-type 1 (HIV-1) infection result from HIV-1 itself or secondarily related
to immunosuppression. In Korea, the number of HIV-1 seropositive populations is
increasing, but little has been known about the neurologic complications of HIV-
1 infection. To investigate the neurologic complications in HIV-1 infected Korean
patients, we performed a cross-sectional study in consecutive admissions to the
Seoul National University Hospital between March 1998 and June 1999. Thirty-
four HIV-1 seropositive patients were included. As a result, a total of 26 HIV-1 re-
lated neurologic complications were identified from 17 patients. Among them, 10
patients showed cognitive/motor abnormalities: 3 HIV-1-associated dementia and
7 possible HIV-1-associated minor cognitive/motor disorder. Neuromuscular com-
plications were found in 10 patients: 9 distal symmetric polyneuropathy, and 1 pos-
sible chronic inflammatory demyelinating polyradiculoneuropathy. In 3 patients
with focal brain lesions, 2 were presumptively diagnosed as having primary CNS
lymphoma, and 1 as having progressive multifocal leukoencephalopathy in the
posterior fossa, based on history, clinical findings, serology, radiological appear-
ances, and response to empirical therapy. Other complications included crypto-
coccal meningitis and only soft neurologic signs without any neurologic disease.
Most of these complications (88%) occurred in the advanced stage of infection.
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and expanded surveillance case definition for AIDS among
adolescents and adults” (Table 1) (14).
The diagnosis of HIV-1-associated cognitive/motor com-
plex was made on the basis of evidence of acquired impair-
ment in at least two cognitive domains without any evidence
of a cerebral mass lesion or active central nervous system (CNS)
infection. We divided them into two categories by their sever-
ity of impairment in activities of daily living: a more severe
form (HIV-1-associated dementia complex, HIV dementia)
and a less severe form (HIV-1-associated minor cognitive/
motor disorder, HIV MCMD) (15). Peripheral neuropathy
was diagnosed on the basis of clinical symptomatology and
electrophysiologic study. In patients with focal brain lesions,
the diagnosis was made based on history, clinical and serolog-
ic findings, radiological appearances, and response to empir-
ical therapy. Cryptococcal meningitis was diagnosed by detec-
tion of its antigen in the patient CSF.
RESULTS
Demographic and general features
Of the 34 patients evaluated, 29 were male and 5 were fe-
male; 23 of the male patients were heterosexual and 5 were
homosexual or bisexual. Of the 5 female patients, 3 were
heterosexual and 1 was a transfusion-related case. None had
a history of intravenous drug use. The mode of transmission
was not identified in one male and one female patient. Their
ages ranged from 23 to 68 yr, with a mean of 43 yr (44 for
males and 38 for females). The mean duration of HIV-1
seropositivity was 40 months. By the “1993 revised classifi-
cation system for HIV infection” 22 were at the clinical stage
C3 and 12 were at the clinical stage less than C3 (C2:3, C1:1,
B2:3, B1:2, A3:1, A2:1, A1:1).
A total of 26 HIV-1-related neurologic complications were
identified from the 17 patients: 23 neurologic complications
out of 15 patients at the clinical stage C3 and 3 out of 2 pa-
tients at the clinical stage less than C3. Eight patients (24%)
had multiple neurologic complications. Six patients (18%)
had neurologic abnormalities as one of the main complaints
and 3 (9%) as initial complaints. The neurologic complica-
tions experienced in these patients are outlined in Table 2.
HIV-1-associated cognitive/motor complex
CASE 1
A 33-yr-old HIV-1-seropositive man with a history of her-
pes zoster and postherpetic neuralgia 2 yr earlier was admit-
ted for evaluation of slowness of speech and movement for 6
months. In addition to psychomotor slowing, he complained
of forgetfulness for a day-to-day event and painful paresthesia
on his soles. Also he had briefly lost his consciousness twice.
Routine bedside Mini-Mental Status Examination (MMSE)
was normal. However, he required additional time and effort
to complete a task and respond a question. Finger tapping
and fist-edge-palm were clumsy, and he had a difficulty in
tandem gait. Deep tendon reflexes were generally brisk, but
the ankle jerks were reduced. Other neurologic examinations
were unremarkable. T2-weighted brain MRI showed diffuse
high signal lesions in periventricular white matter involving
principally in the frontal lobe (Fig. 1A). The electroencephalo-
gram (EEG) showed diffuse bilateral theta activity without
epileptiform discharge. The CSF and NCS were normal. CD4
T-lymphocyte counts were 10/ L(1%) and CD8 were 660/ L
(70%). Stereotaxic brainbiopsy done at the frontal white mat-
ter revealed demyelination with reactive astrocytosis, lipid-
(A) (B) (C)
Asymptomatic, Symptomatic, not     AIDS-indicator
acute (A) or (C) conditions
(primary) HIV or   conditions
PGL
CD4 T-cell categories
A1 B1 C1
(2) 200-499/ L A2 B2 C2
(3) ≤ 200/ L A3 B3 C3
AIDS-indicator T-cell count
PGL: persistent generalized lymphadenopathy.
Clinical category C includes the clinical conditions listed in the AIDS
surveillance case definition.
Table 1. 1993 revised classification system for HIV infection and
expanded surveillance case definition for AIDS among adoles-
cents and adults
Clinical categories
(1) ≥ 500/ L
Clinical stage
C3              A1 to C2
(n=23) (n=3)
HIV-1-associated dementia complex
HIV Dementia 3
HIV MCMD 6 1
Neuromuscular Complication
DSP 8 1
CIDP 1
Focal CNS lesions
PML 1
Primary CNS lymphoma 2
Others
Cryptococcal meningitis 1
Soft neurologic signs only 1 1
HIV dementia: HIV HIV-1-associated dementia complex, HIV MCMD:
HIV-1-associated minor cognitive/motor disorder, DSP: distal symmet-
ric polyneurpathy, CIDP: chronic inflammatory demyelinating polyneu-
ropathy, PML: progressive multifocal leukoencephalopathy, CNS: cen-
tral nervous system.
Table 2. Twenty-six neurologic complications of HIV-1 infection
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laden macrophages, and multinucleated giant cell formation
without definite intranuclear inclusion which was consistent
with HIV-1 related white matter lesion. He was treated with
zidovudine, but progressively deteriorated.  
Three months after the initial evaluation he developed uri-
nary incontinence and showed overt dementic features. Fol-
low-up CSF analysis showed predominantly mononuclear
pleocytosis, an elevated protein level with a normal glucose
concentration. CSF VDRL, cultures, and cytology were neg-
ative. On follow-up MRI, the extent of diffuse confluent high
signal intensity (HSI) on T2-weighted images (T2WI) and
cortical atrophy increased (Fig. 1B).
Over the ensuing 2 months, he became increasingly dement-
ed. His verbal responses were slow, dysarthric, and reduced to
simple phrases. Cognition was severely impaired in all areas,
and there was spastic paraparesis with bilateral extensor plan-
tar and grasp reflexes. He died 6 months after the initial eval-
uation. Autopsy was done and the neuropathologic findings
were consistent with HIV dementia.
HIV-1-associated cognitive/motor complex was found in
10 patients: 1 biopsy-and autopsy-proven HIV dementia, 2
possible HIV dementias, and 7 possible HIV MCMD. Nine
patients were at the clinical stage C3 and only one patient was
at the clinical stage B2. 
The most common early symptom was psychomotor slow-
ing. Almost all patients had a variable amount of psychomo-
tor slowing commonly accompanied by blunting of affect.
The next common complaints were forgetfulness and decre-
ased concentration (Table 3). Initially these symptoms were
usually subtle. Therefore, most of patients did not recognize
the exact onset of the symptoms and sometimes many of these
symptoms were only reported by patients’ families or friends.
However, when examined at advanced stages of HIV demen-
tia, they showed characteristic clinical features including glob-
Fig. 1. T2-weighted brain magnetic resonance images at sixth (A) and ninth (B) month from the symptom onset (Case 1). Progressive
bilateral diffuse white matter high signal intensities more severe in the frontal lobe and cortical atrophy with ventricular enlargement
are noted.
A B
SYMPTOMS No. of patients
Cognitive
Slowness of mental activities                                         10
Easy forgetfulness 6
Difficulty in concentration 5
Motor
Clumsiness in fine motor coordination 2
Loss of balance 2
Tremor 1
Behavioral
Apathy or social withdrawal 6
Agitated psychosis 1
Visual hallucination 1
Aggressive behavior 1
Others
Headache 2
Brief loss of consciousness 2
SIGNS
Generalized hyperreflexia 7
Slowing or clumsiness of RAM 6
Extensor plantar reflex 4
Frontal lobe release signs 3
Saccadic smooth pursuit of ocular movement 2
RAM: rapid alternating movement.
Table 3. Common early symptoms and signs of HIV-1-associat-
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al cognitive impairment.
On standard neurologic examination, most common abnor-
malities were pyramidal tract signs and clumsiness of rapid
alternating movements (Table 3). Routine bedside MMSE
was usually normal, although responses were commonly de-
layed. Five patients had a difficulty in performing serial 7’s
and in recalling a series of objects after 5 min. On detailed
neuropsychologic examination, motor functioning and speed
of processing were most severely impaired and memory, ab-
stract thinking, attention, and concentration were also com-
monly abnormal, while visuospatial function and language
were relatively spared. In case with memory deficit, almost
all patients had more difficulty in free recall than recognition.
Brain MRI was performed in 3 patients with HIV demen-
tia and 1 patient with HIV MCMD. In all cases, MRI showed
various amounts of diffuse cortical atrophy and ventricular
enlargement. In two, MRI revealed diffuse periventricular
HSI on T2WI. CSF study was performed in only one patient.
The findings are described in case 1.
Focal CNS complications
CASE 2
A 38-yr-old HIV-1-seropositive male was admitted because
of severe vertigo, dysarthria, and dysphasia that had gradu-
ally developed and progressed over 1 month. He had a his-
tory of tuberculous lymphadenitis and was suffering from her-
pes zoster on his left chest. Neurologic examinations revealed
bilateral gaze evoked nystagmus and dysmetria more on the
right side. Right facial sensation was a little decreased and
tongue and palatine movement was severely impaired. 
Other cranial nerves, sensation, and strength were normal.
Deep tendon reflexes were generally brisk, but there was no
Babinski sign. Gait was very ataxic. Neither Horner’s signs
nor neck stiffness was present. The CD4 T-lymphocyte count
was 40/ L. Brain MRI showed patch nonenhancing HSI on
T2WI in bilateral medulla and right cerebellum (Fig. 2A).
Viral and Toxoplasma antibody studies were negative. CSF
was acellular with normal protein and glucose levels. All other
CSF studies including VDRL, cultures, and cytology were
negative. Empirical therapy with trimethoprim/sulfamethoxa-
zol and acyclovir were ineffective. Presumptively, the diag-
nosis of progressive multifocal leukoencephalopathy (PML)
in the posterior fossa was made. On follow-up MRI, the extent
of the lesion was increased (Fig. 2). MR angiography showed
no remarkable findings. Follow-up CSF study was normal,
however, JC virus DNA was detected in the CSF by poly-
merase chain reaction. His symptoms worsened progressively
and he died about one year after the onset.
Three patients (8.8%) showed focal brain lesions. Two were
presumptively diagnosed as having primary CNS lymphoma,
and 1 as having PML in the posterior fossa, based on history,
clinical findings, serology, radiological appearances, and
response to empirical therapy. However, the definite diagnoses
were not made due to the lack of pathologic confirmation.
All patients were at the clinical stage C3. None had a pos-
itive serologic test for toxoplasmosis or successful response to
antitoxoplasmosis therapy. The clinical features in 3 patients
with focal CNS complications are outlined in Table 4.
Fig. 2. T2-weighted brain magnetic resonance images at second month from the symptom onset (A), and one-month follow-up image
(B) (Case 2). High signal intensities are noted in medulla and right cerebellar hemisphere, progressed to bilateral cerebellar hemi-
spheric lesions.
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Neuromuscular complications
CASE 3
A 38-yr-old male was admitted with a 2-month history
of fever and burning pain on both soles. After investigation,
diagnoses of Pneumocystis carinii pneumonia and esophageal
candidiasis were made and HIV-1 infection was confirmed
by Western blot. His CD4 T-lymphocyte count was 20/ L.
Neurologic examination showed distal-to-proximal sensory
gradient in the lower extremities and decreased ankle jerks.
Knee jerks were somewhat brisk and Babinski sign was posi-
tive. Other neurologic examinations including muscle strength
were normal. NCS showed markedly decreased amplitude
of compound muscle action potential (CMAP) and sensory
nerve action potential (SNAP), and the slowing of nerve con-
duction velocity (NCV), which was more severe on the lower
extremities without any evidence of spontaneous activity on
EMG. Other biochemical and serologic studies including
vitamin B12 were normal. Amitriptyline was tried with a
limited effect. 
Neuromuscular complications were found in 10 patients.
Nine patients had distal symmetric polyneuropathy (DSP):
7 were symptomatic and 2 asymptomatic. One patient was
presumptively diagnosed as chronic inflammatory demyeli-
nating polyradiculoneuropathy (CIDP). He presented with
progressive symmetric weakness on four extremities (lower
>upper extremity, proximal >distal). He has not been treated
with zidovudine. The serum creatine kinase level was normal.
Electrophysiologic study showed conduction block without
any evidence of myopathy. However, the final diagnosis was
not made because he refused further evaluation. 
Among the 10 patients, 9 were at the clinical stage C3 and
1 was at the clinical stage B2. None had an abnormal vita-
min B12 level or uncorrectable anemia or a history of treat-
ment with neurotoxic antiviral agents more than 3 months.
In the 9 patients with distal symmetric polyneuropathy
(DSP), the most common complaint was tingling or burning
pain in the soles of feet (7 patients), followed by numbness
(4 patients) and weakness (1 patient) of the feet. These symp-
toms were usually confined to the ankles, although sensory
examinations were abnormal above the ankles. Only one
patient had the symptoms extended above the ankles. Sym-
metric complaints were the rule, although one patient had
the symptom on one foot at onset but the other one rapidly
became similarly affected. On neurologic examination, ankle
jerks were exclusively absent or decreased (9 patients). Also,
there was a marked discrepancy between knee and ankle jerks
with the former being excessively brisk compared to the lat-
ter (6 patients). Four patients show a distal-to-proximal gra-
dient to light touch, pinprick, and coldness in the lower
extremities. However, strength and position sensation were
relatively preserved in all patients except one who had severe
polyneuropathy. Electrophysiologic studies showed features
of an axonal degeneration with variable degrees of demyeli-
nation suggestive of a dying-back axonopathy. In spite of the
predominantly sensory complaints, 6 patients had a sensori-
motor polyneuropathy and only 3 had a predominantly sen-
sory polyneuropathy.
Other complications
One patient had cryptococcal meningitis, which was suc-
cessfully treated by amphotericin B. Two patients had pyra-
midal tract signs without any neurologic diseases. Four pa-
tients had paresthesia on the soles without electrophysiologic
evidence of peripheral neuropathy. However, all these patients
Sex/
Risk factor
Symptoms &  Associated
Age (yr) signs conditions
M/38 Bisexual Vertigo, dysarthria Herpes zoster,
dysphagia, Tbc lymphadenitis,
gait disturbance, CMV retinitis
ataxia
M/44 Heterosexual Lt V/F defect,  Pulm Tbc, CMV retinitis,
dysarthria, DSP, cryptococcal-
foot sensory loss, mgts, molluscum-
b/l Babinski signs contagiosum
M/35 Heterosexual Rt FP & hemiparesis, Herpes zoster, PCP
memory loss, CMV esophagitis
generaliezed 
hyperreflexia
C3 70 Normal Nonenhancing
JC virus DNA lesion at medullar
(+) by PCR and cbll (Fig. 1) 
C3 10 Traum Enhancing mass
at Rt occipital 
(Fig. 2)
Clinical 
stage
Brain MRI Outcome CSF
CD4
count (/ L)
Table 4.  The clinical features in 3 HIV-1 (+) patients with focal CNS complications 
Death
Sudden respi-
ratory arrest
Rt weakness 
& ataxia,
incontinence
C3 30 Elevated Multifocal enha-
ncing protein level
lesions with Hmr.
at CC, Lt Parietal
& thalamus  
Lt: left, V/F: visual field, b/l: bilateral, Rt: right, FP: facial palsy, Tbc: tuberculosis, CMV: cytomegalovirus, Pulm: pulmonary, DSP: distal symmetric polyneu-
ropathy, mgts: meningitis, PCP: Pneumocystis carinii pneumonia, PCR: polymerase chain reaction, Cbll: cerebellum, Hmr: hemorrhage, CC: corpus
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had a marked discrepancy between knee and ankle jerks. 
DISCUSSION
The results showed that 17 (50%) out of 34 HIV-1 sero-
positive patients had neurologic complications and 3 (9%)
presented with neurologic complaints. Our figure is a little
higher than that of other major series (4, 5). This seems to
have stemmed from the fact that our patients were skewed
toward the more advanced stage that commonly occurs in
inpatient populations. This was more evident if we analyzed
the patients into two groups as more advanced stage (clinical
stage C3) and less advanced stage (clinical stage less than C3):
15 (68%) out of 22 patients in the former, whereas only 2
(17%) out of 12 patients in the latter had neurologic compli-
cations. Other clinical parameters including age, hemoglobin,
2-microglobulin, and disease duration were not significant-
ly different between the two groups (data not shown). A sig-
nificant difference was observed only in the CD4 T-lympho-
cyte count (51 vs 426/ L). Therefore, it was clear that the
neurologic complications of HIV-1 infection increased with
advancing immunosuppression, in parallel with decreasing
CD4 T-lymphocyte count.
In this study, one of the most common neurologic compli-
cations of HIV-1 infection was cognitive/motor impairment
(29%). It has been known under a variety of terms including
AIDS dementia complex, HIV encephalopathy, subacute
encephalitis, and currently, HIV-1-associated cognitive/motor
complex.
The HIV-1-associated cognitive/motor complex may range
from subtle cognitive abnormalities to a severe dementia.
Working group of American Academy of Neurology AIDS
Task Force divided it into two clinical categories as HIV-1-
associated dementia complex (HIV dementia) and HIV-1-
associated cognitive/motor disorders (HIV MCMD) (15).
The former occurs in advanced stages of HIV-1 infection and
is an AIDS defining manifestation with a variety of demen-
tic symptoms and signs, while the latter does not meet the
usual criteria for dementia because activities of daily living
are not compromised. The two may represent two ends of a
single disease entity with a broad spectrum of clinical pre-
sentations and severity, so patients with a milder form will
invariably progress to a severe form as was one of our patients
who was initially diagnosed as HIV MCMD and finally pro-
gressed to full blown HIV dementia (case 1). However, it is
also suggested that only a small percentage of patients who
diagnosed as HIV MCMD would progress to HIV demen-
tia on follow-up testing and the majority of them reverted
to normal neuropsychological test performance or subclini-
cal cognitive impairment (16). Thus, at present, it is not clear
whether HIV MCMD represents a milder form of HIV de-
mentia or the pathophysiology of these disorders are different.
In this study, 3 patients (14%) out of 22 at advanced stages
of HIV-1 infection showed HIV dementia. The prevalence
of HIV dementia has been reported to range from 7% to 90%
(17). Such a big difference was caused by the heterogeneity
of the population with respect to the stage of HIV-1 infec-
tion and by the variation in the clinical cut-off used to diag-
nose dementia. Now, it is generally accepted that HIV demen-
tia occurs in approximately 20 to 30% of patients with ad-
vanced HIV-1 infection (18) and the annual incidence is about
7% per year after development of AIDS (18-20). 
The clinical features of 10 patients with HIV-1-associated
cognitive/motor complex were similar to the previous descrip-
tions and suggested predominantly subcortical involvement
at least initially (18). Most characteristic early manifestation
was psychomotor slowing. Thus, it was not unusual that
routine MMSE was normal in most of our patients, because
MMSE does not include any subsets for evaluation of psycho-
motor speed. Other common early symptoms were easy for-
getfulness, difficulty in concentration, and waning interest in
work and hobbies resulting in social withdrawal. The friends
or family members of the patients often reported less com-
mon behavioral abnormalities such as shifts in personality
with apathy and social withdrawal and blunting of emotion-
al responsiveness. Common motor complaints included poor
handwriting, insecure balance, and clumsiness. However,
other higher cortical functions were usually preserved until
the dementia is far advanced. The course is usually progres-
sive and most reports have described typical survivals of about
6 to 12 months once the syndrome occurred (18, 21).
No laboratory or neuroimaging study is diagnostic for HIV
dementia so far. Thus, the diagnosis is based on the typical
clinical features and the exclusion of other conditions such as
opportunistic infections and metabolic abnormalities as alter-
native explanations for the syndrome. At the early stage of
disease, the diagnosis is not easy because the initial symptoms
can be confused with depression, anxiety disorder, or the
effects of psychoactive substances. Brain imaging is neces-
sary to exclude other infectious or neoplastic diseases. The
most common findings of brain MRI is nonspecific cerebral
atrophy with or without periventricular white matter signal
abnormalities on T2WI (21, 23, 24). However, brain imag-
ing may be normal (21, 23). CSF study is also essential to rule
out opportunistic infections and syphilis. CSF abnormalities
such as elevated protein, mild mononuclear pleocytosis, in-
trathecal synthesis of anti-HIV IgG, and oligoclonal band
are common. However, these abnormalities are nonspecific
because similar CSF abnormalities can be found in asymp-
tomatic HIV-1-seropositive patients (25). Furthermore, CSF
can be normal, too.
The common neuropathologic findings include multinu-
cleated giant cells, microglial nodules and perivenular inflam-
mation (HIV encephalitis), and diffuse pallor of the myelin
and reactive astrocytosis (HIV leukoencephalopathy) (22). In
general the number of nodules does not correlate with the
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cells derived from macrophages that yield HIV-1 DNA or
antigens correlate with the severity of the dementia (26). 
However, not all the patients with dementia showed these
changes and the pathologic changes may be often less promi-
nent than clinical symptoms (27).
The pathogenesis of HIV dementia remains unknown.
Even in patients with severe dementia, there may be only
mild neuropathologic changes and only a small fraction of
cells within inflammatory nodules or periventricular infiltrates
contain viral antigens. This discrepancy between the small
amounts of replicating HIV-1 and the severity of the demen-
tia suggests that other factors besides direct cellular damage
by HIV-1 may be of importance in pathogenesis.
Despite many unresolved questions in pathogenesis, anti-
retroviral agents are currently used in the treatment of HIV
dementia. At present, zidovudine is the only antiretroviral
agent that has been proven to be effective as documented by
anecdotal case reports (28, 29), open-label observation study
(30), and placebo-controlled trial (31). However, the optimal
dose of zidovudine has not been determined. Recently, the
combination therapy of antiretroviral agents is under inves-
tigation, which is already proven in systemic disease. Other
non-antiviral agents such as memantine (open channel NMDA
antagonist), pentoxyphylline (tumor necrosis factor antago-
nist), and peptide T (pentapeptide analog of gp120) are also
being explored.
The most important differential diagnosis of focal CNS
lesions in patients with HIV-1 infection include cerebral tox-
oplasmosis, primary CNS lymphoma, and PML. Less frquent-
ly tuberculous or fungal abscess, focal viral encephalitis, me-
tastatic Kaposi’s sarcoma or systemic lymphoma, stroke, and
late HIV-1 associate dementia complex can cause focal CNS
lesions. 
In general, the diagnosis can be made efficiently by clini-
cal presentation, neuroimaging, serology, and response to ther-
apy. With respect to temporal progression, cerebral toxoplas-
mosis usually evolves most rapidly over a few days to weeks.
PML is the most indolent, evolving several weeks, while pri-
mary CNS lymphoma pursues an intermediate course (32).
Neuroimaging is most helpful to detect and differentiate
these diseases. PML lesions neither cause a mass effect nor
enhance, whereas mass effect and enhancement are often
noted in the lesion of toxoplasmosis and lymphoma. The con-
trast enhancement is usually more distinct and ring-shaped
in toxoplasmosis and more diffuse in lymphoma. In addition,
toxoplasma abscess usually occurs in the gray matter of the
diencephalon and cortex whereas lymphoma commonly in-
volves the deep white matter adjacent to the ventricles (32,
33). However, this is not always the rule. Thus, definitive diag-
nosis often requires neuropathologic confirmation, especially
after an unsuccessful trial of anti-Toxoplasma therapy (34).
In this study, 3 patients (8.8%) showed focal CNS lesions.
One patient (case 2) had slowly progressive brain stem and
cerebellar dysfunctions. Brain MRI showed nonenhancing
lesions in compatable location with his dysfunctions. Other
investigations and empirical therapy showed no evidences of
opportunistic infection or vasculitis. Thus, the patient was
diagnosed as possible PML in the posterior fossa, which is not
as common as that of hemisphere. Later, JC virus DNA was
detected in the patient’s CSF by PCR. Recently, besides JC
virus, PCR is used as a promising diagnostic tool to detect
Toxoplasma and Epstein-Barr virus DNA in CSF (35-38).
The other two patients had enhancing mass lesions with
only reluctant signs. The clinical presentation favored prima-
ry CNS lymphoma than toxoplasmosis. Moreover, neither
patients were positive for Toxoplasma antibody or responsive
to anti-Toxoplasma therapy. Thus, they were presumptively
diagnosed as possible primary CNS lymphoma although an
absence of antibody and unsuccessful anti-Toxoplasma ther-
apy could not completely exclude the diagnosis of toxoplas-
mosis.
Finally, none had cerebral toxoplasmosis that has been
known to be the most common focal CNS lesion (4 , 6, 39).
Thus, it is likely that the pattern of opportunistic CNS infec-
tion in Korean HIV-1 seropositive populations is different
from that of other countries (4, 5, 41, 42), although a Korean
patient of AIDS with cerebral toxoplasmos was reported (43).
Neuromuscular complications have not received as much
attention as CNS complications because the latter constitute
the most significant neurologic complications in terms of
morbidity and mortality. However, neuromuscular compli-
cations are also common and important causes of morbidity.
There are three kinds of main neuropathic syndromes in
HIV-1 infection: (1) a distal symmetric polyneuropathy (DSP)
with predominantly sensory symptoms that usually occur at
the late stage of infection, (2) an inflammatory demyelinat-
ing polyradiculoneuropathy (IDP) that may occur acutely as
a seroconversion reaction or chronically at early or interme-
diate stage of infection, and (3) mononeuropathy multiplex
that occurs at all stage of infection.
Of these, DSP has been reported as the most frequently
encountered syndrome and clinical and electrophysiologic
abnormalities consistent with DSP may be detected in about
one third of patients (40). At autopsy, however, neuropatho-
logic evidences of DSP may be found in the majority of the
AIDS patients (41). This study proved that DSP is the most
common neuromuscular complication, even though its fre-
quency (26%) is a little less than that of the previous report
(40). 
The clinical features of  9 patients with DSP were also sim-
ilar with those in the previous report, characterized with ini-
tial complaints of paresthesia or numbness almost always be-
ginning in the soles and gradually ascending (4, 41, 44). The
most common sign is depressed or absent ankle jerks relative
to knee jerks. In addition, a marked discrepancy between knee
and ankle jerks is another common early sign, which may
indicate concurrent CNS pathology. The electrophysiologic
features were indicative of distal symmetric degeneration of156 H.J. Kim, S.Y. Kim, K.-B. Lee, et al.
sensory and motor axons, with a similar pattern of other forms
of DSP. 
Although the clinical features of DSP are characteristic, they
are not pathognomonic because some antiretroviral nucleo-
sides, including didanosine, zalcitabine, and stavudine, cause
similar neuropathy (45). In addition, vitamin B12 deficien-
cy, administration of isoniazid for mycobacterial infection
and vitamin B6 deficiency can also cause similar neuropa-
thy. However, none of the patients with DSP were treated
with neurotoxic antiviral agents more than 3 months or had
other causes of peripheral neuropathy, it is likely that their
DSP resulted from the complication of HIV-1 infection. 
Like HIV dementia, the pathogenesis of DSP is still un-
known. Since HIV is not detected systematically within affect-
ed fibers, cytokine-mediated toxic effect has been hypothe-
sized (46). 
The therapy for DSP is limited at present and only directed
at symptoms relief. In contrast to HIV dementia, zidovudine
has not shown consistent benefit toward neuropathic symp-
toms despite responses of other disease markers (47). The im-
pact of other antiretroviral agents that are not neurotoxic is
unknown. 
The other important neuromuscular complication of HIV-
1 infection is IDP. Clinically, HIV-1-associated IDP is indis-
tinguishable from idiopathic IDP. However, in contrast to the
classic CSF profiles of increased protein in the absence of pleo-
cytosis, HIV-1-associated IDP is associated with mild lympho-
cytic pleocytosis (48). It is treated in a manner similar to that
used in patients without HIV-1 infection and the prognosis
is generally good (48, 49). In this study, one patient showed
typical clinical and electrophysiologic pictures of CIDP. Unfor-
tunately, however, we could not make a final diagnosis, because
of lack of the CSF results and treatment response.
It should be mentioned that some caution must be applied
to the interpretation of this study because this was a primari-
ly cross-sectional study even though clinical follow-up was
possible in some patients and pathologic confirmation was
not obtained in most of patients. Therefore, our results might
be different from the real incidence or prevalence of neurolog-
ic complications in HIV-1 seropositive Korean populations.
However, these data are of value in giving an overview of rel-
ative frequencies and characteristic clinical features of neuro-
logic complications. 
In this population of Korean inpatients with HIV-1 infec-
tion, the neurologic complications were frequent and diverse,
often with multiple etiologies in a single patient. They in-
creased with advancing immunosuppression, in parallel with
the decreasing CD4 T-lymphocyte count. General features
and frequencies of them were not so different from those ob-
served in other countries. An important exception is that none
had cerebral toxoplasmosis. 
Even in the absence of neurologic complaints, these patients
should be carefully questioned and examined in search for
underlying neurologic complications that may present high
morbidity and mortality.
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